title: SGS-742 Novartis.
abstract: SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients.
authors.affiliation: The Kingshill Research Centre, Victoria Hospital, Swindon, UK. roger.bullock@kingshill-research.org
authors.forename: Roger
authors.initials: R
authors.lastname: Bullock
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy* / Q000378:metabolism; D018756:GABA Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D018756:GABA Antagonists; D009943:Organophosphorus Compounds; C079148:(3-aminopropyl)(n-butyl)phosphinic acid